Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Choose a calm moment, listen first and give the person time to share how they feel. Here are some other tips on how to help a ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

A newly approved blood test can help rule out some cases based on the amount of amyloid in the brain. A neurology professor ...

Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...